• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Adrian Wiestner, MD, PhD, Discusses the Clinical and Economic Outcomes Associated With the Use of Targeted Kinase Inhibitors in CLL

Article

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL).

Adrian Wiestner, MD, PhD, Investigator, Laboratory of Lymphoid Malignancies, National Heart Lung and Blood Institute, discusses the patient outcomes that clinical trials have demonstrated regarding the use of targeted kinase inhibitors for the management of chronic lymphocytic leukemia (CLL). He notes that, currently, there may not be enough information to develop a comprehensive understanding of the economic implications, but offers that, perhaps looking at chronic myelogenous leukemia (CML) will provide some important relative insight.

This video was taken on Monday, December 10, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Related Videos
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Raj Chovatiya, MD, PhD, MSCI.
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
Galen Shearn-Nance, BS
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.